A diagnostic company dedicated to transforming the landscape of cancer care.
AmoyDx is a global leader in molecular diagnostics dedicated to advancing precision medicine in oncology. Founded in 2008 and headquartered in Xiamen, China, AmoyDx has quickly become a trusted name in the detection of genetic mutations and biomarkers that drive cancer progression. Their innovative diagnostic solutions empower clinicians and researchers worldwide to make informed decisions for personalised cancer treatment.
Extensive oncology diagnostics portfolio: Their company offers a broad range of diagnostic solutions tailored to oncology, providing a complete suite of tools for personalised cancer care.
Exceptional sensitivity and accuracy with user-friendly protocols: Their diagnostic tests are renowned for their high sensitivity and accuracy, combined with easy to-use protocols that ensure reliable results with minimal complexity.
Global regulatory approvals and strong pharmaceutical partnerships: Their products are trusted around the world, with approvals from major regulatory agencies and strong partnerships with leading pharmaceutical companies, reinforcing their commitment to quality and innovation.
Amoy Diagnostics Product Portfolio
At AmoyDx, they specialise in the development and commercialisation of highly sensitive and accurate molecular diagnostic tests. Their product portfolio includes:
Companion Diagnostics: In partnership with leading pharmaceutical companies, they develop companion diagnostics that identify the right patients for targeted therapies, improving treatment efficacy and patient outcomes.
Mutation Detection Kits: Their range of kits target critical cancer-related genes such as EGFR, KRAS, BRAF, ALK, ROS1 and others. These tests are essential tools for clinicians in selecting the most appropriate therapies for their patients.
Liquid Biopsy Technologies: They offer state-of-the-art liquid biopsy solutions that enable non-invasive cancer detection and monitoring through the analysis of circulating tumour DNA (ctDNA). This innovation enables early detection, treatment monitoring and assessment of minimal residual disease.
Innovation and Quality
They are committed to maintaining the highest standards of quality and innovation. Their state-of-the-art R&D facilities and rigorous quality control processes ensure that their products deliver reliable results that healthcare professionals can rely on.
